A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
Othman T, Ruel C, Frankel P, Merleev A, Luxardi G, Maverakis E, Abedi M, Ranganathan R, Zain J, Budde L, Mei M, Rosenberg A, Hoeg R, Costello C, Foss F, William B, Holland H, Villalona-Calero M, Sharon E, Tuscano J. A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses. Blood 2022, 140: 9446-9447. DOI: 10.1182/blood-2022-167173.Peer-Reviewed Original Research